CLOs on the Move

ITC Nexus Dx

www.itcmed.com

 
ITC is a wholly-owned subsidiary of Thoratec and develops, manufactures and markets medical devices used in three distinct segments of the medical field.
  • Number of Employees: 25-100
  • Annual Revenue: $250-500 Million
  • www.itcmed.com
  • 8 Olsen Ave
    Edison, NJ USA 08820-2419
  • Phone: 732.548.5700

Executives

Name Title Contact Details

Similar Companies

American Sports Medicine Institute

American Sports Medicine Institute is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Breckinridge Memorial Hospital

Breckinridge Memorial Hospital is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Hardinsburg, KY. To find more information about Breckinridge Memorial Hospital, please visit www.breckhealth.org

Christian Care Ministry

Christian Care Ministry (CCM) is a non-profit that administers Medi-Share, a healthcare sharing program where Christians come together to share each other`s medical bills. CCM employs more than 700 individuals in Melbourne, FL, Colorado Springs, CO and remotely throughout the United States.

Pascal Metrics

Pascal Metrics is the preeminent provider in the healthcare industry of real-time patient safety and clinical improvement services to reduce patient harm and related cost.

Foghorn Therapeutics

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.